|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors显示文摘在肿瘤免疫学和生物工学的最近的开发使癌症基因治疗和免疫疗法可行。为癌症基因治疗的当前的努力主要集中于使用基因, chemogenes 和肿瘤压制的免疫或基因。对所有这些治疗中央是为基因治疗的有效向量的发展。迄今为止,侵入人体气管粘膜的病菌(副词) 调停了基因治疗是最有希望的途径之一,作为由关于动物肿瘤模型和临床的试用的研究证实了。树枝状的房间(DC ) 是高度有效的,专业化介绍抗原的房间,并且基于 DC 的肿瘤疫苗被认为是有在癌症免疫疗法的许多潜力。有 DC 的种痘与肿瘤肽, lysates,或 RNA 搏动了,或与 apoptotic/necrotic 肿瘤房间装载了,或设计了表示某些 cytokines 或 chemokines 能导致重要的反肿瘤细胞毒素的 T 淋巴细胞(CTL ) 回答和反肿瘤免疫。尽管两个都调停副词的基因治疗和 DC 疫苗的罐头两个都刺激反肿瘤免疫者回答,他们的治疗学的效率被限制了到预防的反肿瘤免疫的产生对与父母肿瘤细胞或到小肿瘤的生长抑制重新质问。然而,这条途径在在动物模型与生长得很好的肿瘤作斗争是失败的。因此,当前的癌症免疫疗法的一个主要战略目标成为了能与生长得很好的肿瘤作斗争的新奇治疗学的策略的发展,自从与重要疾病通常在场的癌症病人的一个好比例,因此类似于真实临床的实践。在这篇论文,我们在调停副词的癌症基因治疗和基于 DC 的癌症疫苗考察最近的进步,并且讨论包括基因治疗和 DC 疫苗的联合免疫疗法。我们强调那联合治疗可以在与作为单音的治疗管理的任何一个形式相比与生长得很好的肿瘤作斗争有一些优点的事实。 | Dajing Xia Terence Moyana Jim Xiang | 2006 | Cell Research2006，16，3： | 7 |
| 2 | Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y_(12 ) signaling pathway显示文摘Ticagrelor is the first reversibly binding oralP2Y_(12) receptor antagonist to inhibit platelet activation and has been approved by the Food and Drug Administration for the treatment of coronary artery disease. At present, the other pharmacological functions of ticagrelor remain poorly understood. The NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome plays a critical role in the innate immune system, but its excessive activation also contributes to the pathogenesis of complex diseases. In this study, we systematically examined the effects of ticagrelor on the NLRP3 inflammasome and found that ticagrelor inhibits NLRP3 inflammasome activation in macrophages independent of its classic inhibitory effect on theP2Y_(12) signaling pathway. Further mechanistic studies demonstrate that ticagrelor attenuates the oligomerization of apoptosis-associated speck-like protein containing a CARD (ASC) by blocking chloride efflux, an effect achieved through the degradation of chloride intracellular channel proteins (CLICs) and blockade of the translocation of CLICs to the plasma membrane. Moreover, experiments on lipopolysaccharide-induced sepsis and alum-induced peritonitis in mice confirmed that ticagrelor mitigates the severity of systemic inflammation independent ofP2Y_(12) receptor antagonism. Importantly, oral administration of ticagrelor rapidly and strongly inhibited NLRP3 inflammasome activation in peripheral blood mononuclear cells from patients with acute coronary syndrome. Overall, our study reveals a novel pharmacological function of ticagrelor in addition to its classic antiplatelet properties, which suggests that ticagrelor may serve as a potential therapeutic agent for use in NLRP3-associated diseases. | Bo Huang Yufeng Qian Shujun Xie Xianhua Ye Hanwen Chen Zhifeng Chen Lihuan Zhang Jinming Xu Hu Hu Shenglin Ma Paul Héroux Di Wang Han-Ming Shen Yihua Wu Dajing Xia | 2021 | Cellular & Molecular Immunology2021，18，5： | 3 |
| 3 | Impact of antitumor regimens on the outcomes of cancer patients with COVID-19:a pooled analysis显示文摘Since the outbreak of coronavirus disease 2019(COVID-19),which is caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)discovered in December 2019,the disease has emerged as a global pandemic(Shi et al.,2020;World Health Organization,2020).Several studies have shown a higher incidence of COVID-19,as well as related poor outcomes in patients with malignancies as compared with those without them(Liang et al.,2020;Tian et al.,2020). | Haohua LU Yu SHI Kelie CHEN Zhi CHEN Haihong ZHU Yuequn NIU Dajing XIA Yihua WU | 2021 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2021，22，10： | 1 |
| 4 | Imbalance of Th17/Treg cells in mice with chronic cigarette smoke exposure显示文摘 | Huaying Wang Weidong Peng Yuesong Weng Huajuan Ying Hequan Li Dajing Xia Wanjun Yu | 2012 | International Immunopharmacology2012，，4： | 1 |
| 5 | Reduced glycodeoxycholic acid levels are associated with negative clinical outcomes of gestational diabetes mellitus显示文摘Gestational diabetes mellitus(GDM) is characterized by glycemia and insulin disorders.Bile acids(BAs) have emerged as vital signaling molecules in glucose metabolic regulation.BA change in GDM is still unclear,which exerts great significance to illustrate the change of BAs in GDM.GDM patients and normal pregnant women were enrolled during the oral glucose tolerance test(OGTT) screening period.Fasting serums were sampled for the measurement of BAs.BA metabolism profiles were analyzed in both pregnant women with GDM and those with normal glucose tolerance(NGT).Delivery characteristics,delivery gestational age,and infant birthweight were extracted from medical records.GDM patients presented distinctive features compared with NGT patients,including higher body mass index(BMI),elevated serum glucose concentration,raised insulin(both fasting and OGTT),and increased hemoglobin A1 c(HbA1c) levels.Higher homeostasis model assessment of insulin resistance(HOMA-IR) and decreased β-cell compensation(i.e.,oral disposition index(DIo)) were also prevalent in this group.Total BAs(TBAs) remained stable,but glycodeoxycholic acid(GDCA) and taurodeoxycholic acid(TDCA) levels declined significantly in GDM.GDCA was inversely correlated with HOMA-IR and positively correlated with DIo.No obvious differences in clinical outcome between the GDM and NGT groups were observed.However,GDM patients with high HOMA-IR and low DIo tended to have a higher cesarean delivery rate and younger delivery gestational age.In conclusion,GDCA provides a valuable biomarker to evaluate HOMA-IR and DIo, and decreased GDCA levels predict poorer clinical outcomes for GDM. | Bo ZHU Zhixin MA Yuning ZHU Lei FANG Hong ZHANG Hongwei KONG Dajing XIA | 2021 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2021，22，3： | 1 |
| 6 | 胆酸通过抑制NLRP3炎症小体活化控制炎症及代谢综合征的发生显示文摘免疫系统和代谢系统的相互作用彼此影响着对方生理功能的正常发挥,对于维持机体的代谢平衡和免疫稳态起着重要的调节作用。当二者的相互调控出现失衡或发生异常时,往往会导致机体相关病理性事件如代谢综合征、自身免疫性疾病、心血管疾病以及肿瘤等的发生。 | Chuansheng Guo Shujun Xie Zhexu Chi Jinhua Zhang Yangyang Liu Li Zhang Mingzhu Zheng Xue Zhang Dajing Xia Yuehai Ke Linrong Lu 王迪 | 2017 | 科学新闻2017，19，4： | 0 |
| 7 | USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer显示文摘This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors(ICIs)by conducting systematic literature search in electronic databases up to May 31,2021.The main outcomes including overall survival(OS),progression-free survival(PFS),objective response rate(ORR),and durable clinical benefit(DCB)were correlated with tumor genomic features.A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies.The Kirsten rat sarcoma viral oncogene homolog G12C(KRAS^(G12C))mutation combined with tumor protein P53(TP53)mutation revealed the promising efficacy of ICI therapy in these patients.Furthermore,patients with epidermal growth factor receptor(EGFR)classical activating mutations(including EGFRL858Rand EGFRΔ19)exhibited worse outcomes to ICIs in OS(adjusted hazard ratio(HR),1.40;95%confidence interval(CI),1.01-1.95;P=0.0411)and PFS(adjusted HR,1.98;95%CI,1.49-2.63;P<0.0001),while classical activating mutations with EGFR^(T790)Mshowed no difference compared to classical activating mutations without EGFR^(T790)Min OS(adjusted HR,0.96;95%CI,0.48-1.94;P=0.9157)or PFS(adjusted HR,0.72;95%CI,0.39-1.35;P=0.3050).Of note,for patients harboring the Usher syndrome type-2A(USH2A)missense mutation,correspondingly better outcomes were observed in OS(adjusted HR,0.52;95%CI,0.32-0.82;P=0.0077),PFS(adjusted HR,0.51;95%CI,0.38-0.69;P<0.0001),DCB(adjusted odds ratio(OR),4.74;95%CI,2.75-8.17;P<0.0001),and ORR(adjusted OR,3.45;95%CI,1.88-6.33;P<0.0001).Our findings indicated that,USH2A missense mutations and the KRAS^(G12C)mutation combined with TP53 mutation were associated with better efficacy and survival outcomes,but EGFR classical mutations irrespective of combination with EGFR^(T790)Mshowed the opposite role in the ICI therapy among lung cancer patients.Our findings might guide the selection of precise targets for effective immunotherapy in the clinic. | DEXIN YANG YUQIN FENG HAOHUA LU KELIE CHEN JINMING XU PEIWEI LI TIANRU WANG DAJING XIA YIHUA WU | 2023 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2023，24，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员